×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild ...
GlobeNewswire
In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and...
3 days ago
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
Yahoo Finance
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript March 28, 2024 Affimed N.V. isn't one of the 30 most popular stocks among hedge...
1 month ago
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European ...
KXAN Austin
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia...
2 weeks ago
Affimed (NASDAQ:AFMD) Shares Pass Below Two Hundred Day Moving Average of $5.23
Defense World
Read Affimed (NASDAQ:AFMD) Shares Pass Below Two Hundred Day Moving Average of $5.23 at Defense World.
2 days ago
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
Yahoo Finance
The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after...
1 month ago
Frontrunners in Bispecific Antibodies
PharmTech
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a...
2 months ago
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Yahoo Finance
Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
2 months ago
Affimed Announces Leadership Change and Organizational Restructuring
Yahoo Finance
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage...
4 months ago
Affimed Reports 2023 Financial Results and Operational Progress
GlobeNewswire
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small...
1 month ago
Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround
Yahoo Finance
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
7 months ago